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The glycoprotein-hormone receptor information
system (GRIS) presents a comprehensive view on
all available molecular data for the lutropin/cho-
riogonadotropin receptor, follitropin receptor, and
thyrotropin receptor G protein-coupled receptors.
It features a mutation database presently contain-
ing 696 point mutations, combined with all se-
quences and the associated homology models.
The mutation information was automatically ex-
tracted from the literature and manually aug-
mented with respect to constitutivity, surface ex-
pression, sensitivity to hormones, and binding
affinity. All information in this integrated system is
presented in a G protein-coupled receptor special-
ist-friendly way. A series of interactive tools such
as rotamer analysis, mutation prediction, or cavity
visualization aids with the design and interpreta-
tion of experiments. A universal residue numbering
system has been introduced to ease database
searches as well as the use of the information in
conjunction with literature data from diverse ori-
gins. Users can upload new mutations. GRIS is
freely accessible at http://gris.ulb.ac.be/. (Molecu-
lar Endocrinology 20: 2247–2255, 2006)
GPROTEIN-COUPLED RECEPTORS (GPCRs) area large superfamily of membrane receptors that
are involved in a wide range of signaling activities.
They share a tertiary structure characterized by an
extracellular amino terminus, followed by seven trans-
membrane -helices connected by three extracellular
and three intracellular loops, with the C terminus in the
cytoplasm. This so-called “serpentine domain” forms
the basis for the classification of GPCRs into classes
displaying sequence identities (1). Class A, or rhodop-
sin-like GPCRs, form the largest class. Other classes
are class B (secretin, glucagon, pituitary adenylate
cyclase activating peptide receptors, etc.), class C
(calcium sensing and metabotropic glutamate recep-
tors), and a few smaller classes. GPCRs are activated
by extracellular ligands. Most class A receptors have a
relatively short N-terminal domain and can be acti-
vated by small ligands that bind in a cavity between
the seven transmembrane helices (Fig. 1) or by pep-
tidic ligands of which a part will be directed in the
same cavity (Fig. 1). Class B and C receptors have an
extensive extracellular N-terminal domain that is in-
volved in ligand binding (2, 3). For the class B re-
ceptors, it has been suggested that the largest part
of the peptide agonist forms an -helix that binds to
the N-terminal domain of the receptor while the
N-terminal residues of the ligand dock between the
transmembrane helices (TMs), thereby mimicking a
class A receptor’s small ligand (2). For the class C
receptors, which are constitutive dimers, it is known
that the small ligand (e.g. calcium or glutamate)
binds to the N-terminal domain of the receptor. The
prevailing hypothesis is that activation takes place
via conformational changes of the dimeric ectodo-
main, resulting in an ill-defined effect on the struc-
ture of the serpentine dimer (3). Glycoprotein-hor-
mone receptors (GpHRs) belong to class A from an
evolutionary point of view (1, 4–6). However, they
comprise a large, extracellular, N-terminal domain
that, just as in class B and C receptors, is involved
in ligand binding (Fig. 1). Upon activation, it is be-
lieved that the ectodomain switches from an inverse
agonist of the serpentine domain into a full agonist,
and initiates signal propagation (7). For the GpHRs,
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nothing is firmly known yet about the transduction of
this signal (8).
GpHRs consist of three members: the thyrotropin
receptor (TSHR), the follitropin receptor (FSHR), and
the lutropin/choriogonadotropin receptor (LHR/CGR).
Their large N-terminal domains consist essentially of
leucine-rich repeats (LRRs) (9) that are responsible for
selective, high-affinity hormone binding that triggers
the signal transduction (10–15).
Many natural gain-of-function mutations of GpHRs
have been identified in patients suffering from target
tissue autonomy resulting, for the TSHR, in hereditary
(16) or congenital (17) toxic thyroid hyperplasia (18)
and toxic thyroid adenoma (19) or, for the LHR/CGR, in
pseudo-precocious puberty of the male (20). These
mutations are mainly observed in the transmembrane
portion of the LHR/CGR and the TSHR (19, 21). Anal-
yses of the mutant receptors, using molecular models
of GpHRs built using the bovine rhodopsin structure
(22, 23) as a template, are yielding information on the
mechanism of activation (5, 24, 25). The FSHR seems
more resistant to constitutive activation. Only four nat-
ural mutants were reported, characterized by persis-
tent male fertility despite pituitary insufficiency (26),
and by ovarian hyperstimulation syndrome (25, 27,
28).
Understanding of the structure-function relation-
ships of the GpHR subfamily requires that mutation
data gathered from one receptor can be interpreted
in the light of results obtained with another. Zhang et
al. (29) introduced a salt bridge between the helices
III and VI in the human LHR/CGR. Mapping a large
series of mutations on a homology model, conclu-
sions could be drawn about the importance of in-
teractions between these two helices for LHR/CGR
activation. Angelova et al. (30) used sequence align-
ments to combine mutation data using a schematic
model of the generic helix pair VI–VII to study inter-
actions between these two helices from mutation
data in multiple receptors. Tao et al. (31) use multi-
ple sequence alignments and a homology model to
merge mutation data and to draw conclusions about
this same helix pair in the FSHR. Fanelli et al. (32)
combined a series of homology models of the LHR/
CGR mutated at residue M398 (2.43) and site-di-
rected mutagenesis experiments to study the mech-
anism of constitutivity induced by mutations at this
site.
These examples that shed light on the sequence-
structure-function relationships of GpHRs all have in
common that extensive integration of heteroge-
neous data was the key to success. To support our
own studies in this field (7, 14, 25, 33), we have
designed a GpHR information system. Called glyco-
protein-hormone receptor information system
(GRIS), it holds all 51 presently known GpHR se-
quences (classified and aligned) and 696 mutations
that were automatically extracted from the literature
(34) and manually annotated. Homology models for
all TM domains and ectodomains have been built
and are fully integrated with the sequence and mu-
tation information. A series of fully interactive user-
friendly facilities allow GpHR researchers to intu-
itively use powerful software that uses the system
for the design and interpretation of experiments.
GRIS is freely available at http://gris.ulb.ac.be/. The
software and scripts to build GRIS are sufficiently gen-
eral to be used for other GPCR families, and are avail-
able from the authors upon request.
RESULTS AND DISCUSSION
The four basic functions of an information system are
browsing, retrieval, query, and inferencing (35).
Browsing
Browsing is important to show the user scientists the
context of data, such as similar data for related recep-
tors, different experiments for the same receptor, etc.
GRIS uses the hyperlink tables of the GPCR database
(GPCRDB) (36) for this purpose, and the information
about mutations along with links to SwissProt (37),
PubMed (http://www.pubmed.com), etc. adds further
browsing facilities. GRIS is also rich in internal hyper-
links to facilitate rapid navigation between mutants,
sequences, structure models, and computing facili-
ties. Figure 2 shows a so-called snake-plot for a re-
ceptor (38).
The residues that are shown on a white back-
ground are hyperlinked to the corresponding muta-
Fig. 1. Schematic Representation of Class A GPCR-Ligand
Interactions
Left, Small ligand (yellow ellipsoid) binds in a cavity be-
tween the helices of GPCRs with a short N terminus. Center,
A part of the peptidic ligand binds in the cavity between the
helices of GPCRs with a short N terminus, whereas the rest
of the ligand contacts other parts of the receptor, e.g. N
terminus and extracellular loops. Right, Glycoprotein hor-
mones bind to the large extracellular domain of GpHRs.
Signal transduction in GpHRs from the ectodomain via the
helices to the G protein is poorly understood. The extracel-
lular domain was drawn with YASARA (http://www.
yasara.org) using actual coordinates from the human FSHR
structure (PDB code: 1XWD).
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tion information, which is, in turn, hyperlinked to a
three-dimensional (3D) model with the mutated res-
idue indicated (see Fig. 3 for an example). All mu-
tation information is hyperlinked to the correspond-
ing MuteXt (34) entry in the GPCRDB so that all
relevant sentences from the underlying articles are
rapidly accessible too. GRIS makes extensive use of
the Jmol software (http://www.jmol.org) to allow for
browsing through 3D models of the receptors (see
Figs. 3 and 7 for examples).
Retrieval
Retrieval is important to allow users to evaluate data
and results with in-house software they are familiar
with. For example, GRIS presents all homology mod-
els in the standard PDB format which means that any
in-house molecular visualizer can be used to study the
models beyond the facilities GRIS offers. After design-
ing a mutant, the user can obtain the coordinates of
the mutant structure. Sequences can be downloaded
in both aligned and raw format. All mutant information
can be downloaded as a flat file (human and comput-
er-readable file) for use in other (query) software.
Query
The mutant data can be inspected in many ways. The
snake-like plots (see Fig. 2) present mutants in the format
most commonly used in the GPCR field. The multiple se-
quence alignment that is hyperlinked to the mutation infor-
mation gives the user quick access to mutations of the
same residue in different receptors (see Fig. 4). The most
direct query facility is provided by the query form as shown
in Fig. 5, which allows the user to search for mutations as a
function of species, receptor type, structure element, resi-
due position, and mutation type. The mutation data was
obtained using MuteXt (34) (seeMaterials and Methods for
abrief descriptionof theMuteXtmethodology), andmissing
information about the expression level, the degree of con-
stitutive activity obtained with the mutation, and the ligand
binding activity, weremanually extracted from the literature
and added to the system. Automated MuteXt updates are
scheduled three times per year. Because it is not possible
to automatically extract all mutant information, we added a
facility that allows users to interactively add mutation infor-
mation to GRIS. Upon reception of a GRIS account, users
can rapidlyuploadmissingGpHRmutations thathavebeen
published in the literature by completing a simple mutation
contribution form (seesupplemental data, publishedonThe
EndocrineSociety’s JournalsOnlinewebsite at http://men-
d.endojournals.org). After revision by the curator, the new
mutations are added to the public database. BecauseMu-
teXt is an automated literature retrieval method, it has its
limitations. MuteXt needs to access online full-text articles.
The availability of these articles is, in turn, dependent on the
subscriptions of the institution MuteXt is run from. GRIS
users are encouraged to report any missing references.
Three numbering schemes commonly used in the
literature for the TM domains are the GPCRDB stan-
dard (36), the Ballesteros and Weinstein scheme (39),
and the SwissProt numbers (37). All three numbering
systems were implemented into GRIS to allow for
meaningful comparisons of GRIS data and results with
the literature and other external sources of informa-
tion. The location of residues can also be visualized
using publication-ready YASARA (40) pictures (see
Fig. 6).
Inferencing
The most important reason underlying our design of
GRIS is the desire to interpret results and to design
new experiments, especially point mutations that can
shed light on GpHR related questions. For this pur-
pose, a series of WHAT IF (41) mutant design options
has been prepared for output via Jmol. These facilities
include rotamer prediction (42), cavity visualization,
mutant prediction, and the generation of detailed in-
formation about one residue. Figure 7 illustrates some
of these facilities.
The rotamer analysis module of GRIS (Fig. 7A) has
already shown to be an excellent mutation prediction
tool in a recent experiment (43). A constitutively active
M626I (6.37) mutation was found in the TSHR in af-
Fig. 2. Snake-Like Plots for the Presentation of Mutants
The colors of the circles relate to the physicochemical
properties of the residues. Residues on a white background
are hyperlinked to mutation data. A shows the 7TM domain
including helix 8, and B shows the ectodomain where the
black ladders represent the inner strands of the LRRs. The
big blue circles hyperlink from the 7TM domain to the corre-
sponding ectodomain and vice versa. Snake-like plots are
generated with the residue-based diagram generator (RbDg)
(38).
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fected members of a family with nonautoimmune hy-
perthyroidism. The rotamer analysis using GRIS indi-
cated a severe bump of the mutant residue with I515
(3.46) in the TSHR. We tried rotamer distributions for a
few residue types at position I515 in the TSHR-M626I
variant. A methionine at position 515 looked most
promising and the double mutant I515M/M626I was
constructed in the TSHR wild type. Experiments
showed that the constitutive activity obtained from the
M626I mutation was reduced again to wild-type activ-
ity by I515M.
Although GpHRs are activated by their peptide hor-
mone ligands that bind to the extracellular domain, a
small organic molecule has previously been designed
that acts as a FSHR antagonist (44). Because impair-
ment of FSHR function by mutations can lead to de-
creased fertility or infertility (45–47), such drugs are
becoming promising nonsteroidal contraceptive
agents. Rational drug design requires knowledge
about cavities in the target receptor, and the identifi-
cation of residues around such a cavity is obviously
important (Fig. 7B).
A previous study by our group stressed the impor-
tance of a hydrogen bond network between TM6 and
TM7 of the human TSHR to maintain the inactive state
of the receptor (24). We reanalyzed all single mutations
with the mutation prediction module of GRIS and
came to the same conclusions. Mutations D633N
Fig. 4. N-Terminal Part of the Multiple Sequence Alignment
of Mutated GpHRs with Mutations Indicated
The blue residues are hyperlinked to the mutation informa-
tion. The consensus residues (top sequence) are hyperlinked
to tables of all mutations observed at that position in any
receptor.
Fig. 3. Example of Mutant Visualization in an Interactive 3D Model
The left panel holds the model. The right panel provides view options such as displaying a smooth ribbon, displaying residues
in the environment, labeling residues, etc. This visualization is based on the popular Jmol (http://www.jmol.org) package. Jmol
works under Java, so that GRIS users do not need to install any visualization software.
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(6.44) and N674A (7.49) still maintain hydrogen bonds
between TM6 and TM7 as described in the previous
publication (24). GRIS predictions of the substitutions
D633A and N674D show that a TM6–TM7 link in this
region cannot be maintained, either by total disruption
of all hydrogen bonds (D633A) or by electrostatic re-
pulsion (N674D), which is associated with a strong
increase in constitutive activity (48).
Another study by our laboratory elucidated a link
between constitutive activity and promiscuous activa-
tion of the FSHR (25) following the discovery of a
mutation D567N (6.30) in a patient with spontaneous
ovarian hyperstimulation syndrome. Using molecular
modeling, we concluded that this mutation was able to
break an ionic interaction between D567 (TM6) and
R467 (3.50) (TM3). Inspecting the molecular model of
Fig. 6. High-Quality Cartoon Shot of a Residue and Its Direct Environment
A, Colors of the backbone and residues relate to the secondary structure. The figure shows W494 (4.50) from TM4 hydrogen
bonding (yellow dotted line) with N403 (2.45) from TM2 in human FSHR. B, A complete view of the human FSHR serpentine
domain colored in rainbow gradient. The same residue W494 (4.50) is selected in gray. Pictures were made with YASARA
(http://www.yasara.org).
Fig. 5. The Mutation Query Form
The mutation query form allows the user to search for mutations according to the receptor, species, structural region,
constitutivity, and binding affinity. It is also possible to search for specific substitutions (e.g. Asp3Asn) or to search for mutations
at a certain position according to one of the three numbering schemes.
Van Durme et al. • GRIS Mol Endocrinol, September 2006, 20(9):2247–2255 2251
human FSHR from GRIS, it is easy to see that these
residues can indeed interact in the wild-type receptor.
Aided by the in silico mutation tool and mutation in-
formation of the same residue position in other recep-
tors from GRIS, it is straightforward to design a panel
of mutations in the human FSHR that either maintain
this interaction or break it, so one can draw firm con-
clusions from the modeling and experimental data
(25).
Each of these examples shows that GRIS is able to
predict the effect of mutations and to aid researchers
in the GpHR field to rationally set up their experiments.
Although the homology models of the GpHR
ectodomain based on the human FSHR can be treated
as highly reliable models, there are some limitations on
the homology models of the transmembrane domain
of GpHRs provided by GRIS. Although the 3D coordi-
nates of bovine rhodopsin provide the best template to
model the transmembrane domain of GpHRs, it is not
the perfect template for several reasons (49). First,
sequence analyses show that the opsin family differs
very much from the other class A GPCRs. This is
particularly true for interhelical loops, where identity is
so low that it precludes a reliable alignment. Second,
the crystal structure of bovine rhodopsin is an antipa-
rallel and thus unnatural dimer. Third, the available
bovine rhodopsin structure is the inactive form of the
protein. Predictions on constitutively activating muta-
tions should be made with caution.
When additional class A GPCR structures become
available, GRIS will be updated by including novel
GpHR homology models along with the current mod-
els based on bovine rhodopsin. This should allow for
progressive upgrading of present models.
MATERIALS AND METHODS
GRIS has been written in Python (http://www.python.org) and
uses CGI scripts for interactive activation of options. Snake-
Fig. 7. Facilities to Support the Design of Mutations in GpHRs
A, A rotamer distribution for histidine at position 467 (3.50) in human FSHR is shown. A rotamer distribution represents the
likelihood of finding a mutated residue side chain at a certain position. The more populated an island is in the distribution, the more
likely it is that the residue will adopt that rotamer. B, All residues lining a cavity in the bovine TSHR are colored yellow. Even though
we do not expect GpHRs to possess a cavity similar to the class A amine receptors, the presence of this cavity generates
suggestions for mutations. C, Subset of the detailed information listed for Asp582 (6.44) in rat LHR. Listed residues can be
selected and presented in a high-quality publication-ready YASARA picture like the example shown in Fig. 6. D, Residue 502 (3.33)
(thicker sticks) in rat TSHR before (left) and after (right) mutating it from Val to Asp.
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like plots are produced with the residue-based diagram gen-
erator (RbDg) (38). 3D structures are presented with Jmol
(http://www.jmol.org). WHAT IF (41) is used for sequence
alignments, homology modeling, interactive protein structure
analysis, and mutant predictions. The sequence alignment
profile needed by WHAT IF was hand-optimized for GpHR
purposes. The conversion of the sequence alignment to col-
ored HTML pages was carried out using the MView program
(50).
MuteXt (34) is used to identify and extract single point
mutations from literature full-text articles by pattern matching
along with names of the concerned GPCR names and organ-
ism types. Extracted mutation data are checked by two au-
tomated validation filters. The first filter verifies that the mu-
tated amino acids are at the indicated positions in the
corresponding GPCR sequence(s). The second filter looks for
minimal word distances between mutations, protein names,
and organisms to discriminate between possible multiple
sequences. Validated mutations are integrated into the
GPCRDB (36). GpHR-related mutations are then imported
into GRIS. At this stage of reviewing, falsely selected papers
(not GpHR related) are removed from the database. The
retrieved literature is read by the GRIS database curator and
mutation annotations regarding constitutivity, cell surface ex-
pression, and ligand binding are added manually.
YASARA (40) is used to produce publication-ready 3D
structure figures and to perform energy minimization of the
GpHR models. GRIS uses the PostGres (http://www.post-
gresql.org) relational database system for data storage. GRIS
hyperlinks from several locations to the GPCRDB for easy
access to other forms of data (genomic information, phylo-
genetic trees, discussion groups, etc.).
All 3D models of GpHRs were constructed using the FSH-
FSHR complex structure (9) as template for the ectodomain
and the bovine rhodopsin structure (23) as template for the
transmembrane domain. For completeness, the hormones
were also modeled together with the ectodomains when the
hormone sequence was available. Homology models were
built using WHAT IF’s standard modeling procedure. Only the
structural conserved regions, which could be unambiguously
aligned, were modeled. For the ectodomain, these include all
nine LRRs and the - and -subunits of the hormone. The
transmembrane domain includes all seven transmembrane
helices and the eighth cytoplasmic helix. Interhelical loops
were not modeled. To remove bumps and correct the cova-
lent geometry, all structures were energy-minimized with
YASARA (40) by applying the Yamber2 force field, using a
7.86-Å force cutoff. After removal of conformational stress by
a short steepest descent minimization, the procedure con-
tinued by simulated annealing (time step, 2 fsec; atom veloc-
ities scaled down by 0.9 every 10th step) until convergence
was reached, i.e. no energy improvement was found for 200
steps. The set of energy minimized models and the set of
“raw” models (not energy minimized with YASARA) are both
available for download from the website. WHAT IF structure
integrity check reports are available from the web site as well.
The function of residues in GPCRs is mainly determined by
their location (51). Therefore, a mutation of a residue at a
certain position in one receptor is likely to have a similar effect
as the mutation of a different residue at the equivalent posi-
tion in another receptor. The structural equivalence can
therefore be used to transfer information about mutations in
one GpHR to all other GpHRs. To aid this transfer of infor-
mation, a common residue numbering scheme for all GpHRs
has been implemented. For the transmembrane domain, we
have implemented the numbering schemes of SwissProt (37),
the GPCRDB (36), and Ballesteros and Weinstein (39). Nei-
ther the GPCRDB, nor Ballesteros and Weinstein numbered
the ectodomains, so we devised a scheme that looks like
both these. We used the residue naming scheme for the
LRRs by Smits et al. (14) and called the residues in the
inner-face -strands X1-X2-L1-X3-L2-X4-X5, where the side
chains of the L1 and L2 residues (mostly leucines, but always
hydrophobic) are pointing to the inside of the protein. The X3
residue is mostly hydrophilic and points to the outside. We
have chosen to denote the X3 residue of the first LRR as
1050, X3 of the second LRR as 2050, and so on. The num-
bering within each LRR counts down from the XX50 residue
to the previous LRR and up to the next.
The specific residues discussed in this manuscript are
numbered according to the SwissProt numbering scheme
(37) followed by the Ballesteros and Weinstein general num-
bering (39), e.g. D633N (6.44).
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